Skip to the page

Data / Drug companies / Oseltamivir phosphate

Oseltamivir phosphate: 37 companies and 109 products in the FDA NDC directory

Oseltamivir phosphate is listed in the FDA National Drug Code Directory by 37 companies, with 109 products in commercial distribution. 106 of the products (97.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; powder, for suspension; for suspension, and the newest product started marketing on October 9, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
37
Products
109
Generic (ANDA) products
106 (97.2%)
Application numbers
31
Routes
Oral
Brand names
Tamiflu, Oseltamivir
openFDA record search
api.fda.gov

Companies that list oseltamivir phosphate

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
A-S Medication Solutions7capsule; powder, for suspensionGeneric drugs (ANDA)July 13, 2023
Proficient Rx LP7capsule; powder, for suspensionGeneric drugs (ANDA)October 5, 2018
Preferred Pharmaceuticals Inc.6capsule; for suspensionGeneric drugs (ANDA)January 28, 2026
Sportpharm LLC6capsuleGeneric drugs (ANDA)October 8, 2018
Asclemed USA, Inc.5capsule; powder, for suspensionGeneric drugs (ANDA)October 5, 2018
Alvogen Inc.4capsule; powder, for suspensionGeneric drugs (ANDA)November 1, 2017
Camber Pharmaceuticals, Inc.4capsule; powder, for suspensionGeneric drugs (ANDA)March 28, 2022
Epic Pharma, LLC4capsule; powder, for suspensionGeneric drugs (ANDA)August 2, 2022
Exelan Pharmaceuticals Inc.4capsule; for suspensionGeneric drugs (ANDA)December 1, 2023
Lannett Company, Inc.4capsule; suspensionGeneric drugs (ANDA)July 13, 2023
Lupin Pharmaceuticals, Inc.4capsule; powder, for suspensionGeneric drugs (ANDA)February 21, 2018
Novadoz Pharmaceuticals LLC4capsule; powder, for suspensionGeneric drugs (ANDA)May 6, 2022
Redpharm Drug4capsuleGeneric drugs (ANDA)May 15, 2023
Strides Pharma Science Limited4capsule; powder, for suspensionGeneric drugs (ANDA)October 24, 2022
Zydus Pharmaceuticals USA Inc.4capsule; for suspensionGeneric drugs (ANDA)September 14, 2017
Genentech, Inc.3capsule; powder, for suspensionNew drug applications (NDA)March 21, 2011
Laurus Labs Limited3capsuleGeneric drugs (ANDA)May 2, 2024
Macleods Pharmaceuticals Limited3capsuleGeneric drugs (ANDA)September 21, 2017
Remedyrepack Inc.3capsuleGeneric drugs (ANDA)October 9, 2026
Shandong New Time Pharmaceutical Co., Ltd.3capsuleGeneric drugs (ANDA)July 9, 2025
Zhejiang Poly Pharm. Co., Ltd.3capsuleGeneric drugs (ANDA)December 31, 2025
Zydus Lifesciences Limited3capsuleGeneric drugs (ANDA)February 24, 2017
NuCare Pharmaceuticals,Inc.2powder, for suspension; for suspensionGeneric drugs (ANDA)May 28, 2020
Proficient Rx LP2capsuleGeneric drugs (ANDA)August 25, 2020
Ajanta Pharma USA Inc.1for suspensionGeneric drugs (ANDA)May 28, 2020
Alembic Pharmaceuticals Inc.1for suspensionGeneric drugs (ANDA)June 29, 2026
Alembic Pharmaceuticals Limited1for suspensionGeneric drugs (ANDA)June 29, 2026
Amneal Pharmaceuticals NY LLC1for suspensionGeneric drugs (ANDA)March 5, 2018
Aurobindo Pharma Limited1powder, for suspensionGeneric drugs (ANDA)May 10, 2024
AvKARE1for suspensionGeneric drugs (ANDA)August 26, 2019
Cipla USA Inc.1for suspensionGeneric drugs (ANDA)January 16, 2023
Hec Pharm USA Inc.1suspensionGeneric drugs (ANDA)March 25, 2026
Leading Pharma, LLC1suspensionGeneric drugs (ANDA)June 1, 2022
MSN Laboratories Private Limited1capsuleGeneric drugs (ANDA)May 22, 2020
Oryza Pharmaceuticals Inc.1powder, for suspensionGeneric drugs (ANDA)October 19, 2025
Slate Run Pharmaceuticals, LLC1capsuleGeneric drugs (ANDA)January 1, 2024
Teva Pharmaceuticals USA, Inc.1powder, for suspensionGeneric drugs (ANDA)July 10, 2019

Dosage forms

Dosage formProductsShare
Capsule7972.5%
Powder, for suspension1513.8%
For suspension1110.1%
Suspension43.7%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)10697.2%
New drug applications (NDA)32.8%

Pharmacologic classes

ClassProducts
Neuraminidase Inhibitor106

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.